Risperdal's long shadow over Alkermes

Johnson & Johnson subsidiary Janssen Pharmaceutica NV and partner Alkermes Inc. are keeping mum about the reasons behind last week's non-approvable letter from FDA for Risperdal Consta long-acting risperidone microsphere injection to treat psychoses in schizophrenia patients. But the damage to ALKS's stock, which plummeted 72% last week, could endanger its pending acquisition of Reliant Pharmaceuticals LLC.

JNJ (New Brunswick, N.J.) said it was confident that it could resolve the FDA's questions about certain aspects of pre-clinical data, but would not elaborate on the nature of the questions. Spokesperson Melissa Katz did say that

Read the full 934 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE